Takeda Pharmaceutical (BOVESPA:TAKP34) - Prezzo delle azioni, notizie e analisi

TAKP34 Panoramica delle azioni

Takeda Pharmaceutical Company Limited si occupa di ricerca, sviluppo, produzione, commercializzazione e concessione in licenza di prodotti farmaceutici in Giappone e a livello internazionale.

Informazioni sull'azienda

TAKP34 analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	3/6
Prestazioni passate	1/6
Salute finanziaria	3/6
Dividendi	4/6

Premi

Negoziato a 41.1% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 22.15% all'anno

Analisi del rischio

Il debito non è ben coperto dal flusso di cassa operativo

Le azioni sono altamente illiquide

I margini di profitto (3.4%) sono inferiori rispetto allo scorso anno (7.3%)

Grandi elementi una tantum che incidono sui risultati finanziari

+ 1 più rischio

Takeda Pharmaceutical Company Limited Concorrenti

Hypera

BOVESPA:HYPE3

R$15.2b

Ouro Fino Saúde Animal Participações

BOVESPA:OFSA3

R$1.2b

Sun Pharmaceutical Industries

NSEI:SUNPHARMA

₹4.4t

Jiangsu Hengrui Medicine

SHSE:600276

CN¥300.1b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Takeda Pharmaceutical
Prezzi storici delle azioni
Prezzo attuale dell'azione	JP¥81.84
Massimo di 52 settimane	JP¥84.50
Minimo di 52 settimane	JP¥66.46
Beta	0.50
1Variazione di 1 mese	1.19%
Variazione a 3 mesi	3.13%
Variazione di 1 anno	19.79%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	16.91%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	TAKP34	BR Pharmaceuticals	BR Mercato
7D	3.2%	-5.2%	0.3%
1Y	19.8%	-0.9%	7.0%

Ritorno vs Industria: TAKP34 ha superato il BR Pharmaceuticals che ha restituito -0.9 % nell'ultimo anno.

Rendimento vs Mercato: TAKP34 ha superato il mercato BR che ha restituito 7 % nell'ultimo anno.

Volatilità dei prezzi

Is TAKP34's price volatile compared to industry and market?
TAKP34 volatility
TAKP34 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.4%
10% most volatile stocks in BR Market	8.8%
10% least volatile stocks in BR Market	2.3%

Prezzo delle azioni stabile: Il prezzo delle azioni di TAKP34 è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di TAKP34 nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1781	49,281	Christophe Weber	www.takeda.com

Takeda Pharmaceutical Company Limited si occupa di ricerca, sviluppo, produzione, commercializzazione e concessione in licenza di prodotti farmaceutici in Giappone e a livello internazionale. Offre prodotti farmaceutici nei settori della gastroenterologia, delle malattie rare, delle terapie plasmaderivate, dell'immunologia, dell'oncologia e delle neuroscienze. L'azienda fornisce i suoi prodotti con i marchi Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA e Alunbrig.

Takeda Pharmaceutical Company Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Takeda Pharmaceutical con la sua capitalizzazione di mercato?
TAKP34 statistiche fondamentali
Capitalizzazione di mercato	R$253.31b
Guadagni(TTM)	R$5.64b
Ricavi(TTM)	R$165.93b

44.9x

Rapporto P/E

1.5x

Rapporto P/S

TAKP34 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
TAKP34 Conto economico (TTM)
Ricavi	JP¥4.41t
Costo del fatturato	JP¥1.50t
Profitto lordo	JP¥2.92t
Altre spese	JP¥2.77t
Guadagni	JP¥149.92b

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Oct 31, 2024

Utile per azione (EPS)	94.60
Margine lordo	66.07%
Margine di profitto netto	3.40%
Rapporto debito/patrimonio netto	70.3%

Come si è comportato TAKP34 nel lungo periodo?

Vedi performance storica e confronto

Dividendi

4.6%

Rendimento attuale del dividendo

197%

Rapporto di remunerazione

TAKP34 Panoramica delle azioni

Premi

Analisi del rischio

Takeda Pharmaceutical Company Limited Concorrenti

BOVESPA:HYPE3

R$15.2b

BOVESPA:OFSA3

R$1.2b

NSEI:SUNPHARMA

₹4.4t

SHSE:600276

CN¥300.1b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Recent updates

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Takeda Pharmaceutical Company Limited Proposes Dividend

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Announces S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year 2023

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda Pharmaceutical Company Limited Announces FDA Approves the Supplemental Biologics License Application for the Expanded Use of TAKHZYRO

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Takeda Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on May 11, 2023

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda